title: Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss.
abstract: OBJECTIVE
  To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.
  
  
  METHODS
  The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).
  
  
  RESULTS
  Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.
  
  
  CONCLUSIONS
  A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.
authors.affiliation: 2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Dendrinos
authors.forename: I
authors.initials: I
authors.lastname: Kalogirou
authors.forename: E
authors.initials: E
authors.lastname: Makrakis
authors.forename: T
authors.initials: T
authors.lastname: Theodoridis
authors.forename: E A
authors.initials: EA
authors.lastname: Mahmound
authors.forename: V
authors.initials: V
authors.lastname: Christopoulou-Cokkinou
authors.forename: G
authors.initials: G
authors.lastname: Creatsas
mesh_terms: D000026:Abortion, Habitual / Q000188:drug therapy*; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011256:Pregnancy Outcome; D019851:Thrombophilia / Q000188:drug therapy; D000078222:Tinzaparin
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin; D001241:Aspirin